The completed PMS facility spans over 80,000-sq-ft with an additional 20,000-sq-ft reserved for future growth and expansion.

Researchers suggest targeting inflammation may offer a promising therapeutic strategy at the intersection of cancer and cardiovascular disease.

VantAI's AI platform will accelerate programmable protein interaction therapies across Halda's cancer and immunology indications.